Deterioration of fracture healing in the mouse model of NF1 long bone dysplasia

Bone

Volumn 51, Issue 4, 2012, Pages 651-660

  El Khassawna, T ^a,b   Toben, D ^a,b   Kolanczyk, M ^a,c   Schmidt Bleek, K ^a   Koennecke, I ^a,b   Schell, H ^a   Mundlos, S ^b,c   Duda, G N ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

Bone healing; Neurofibromatosis; NF1; Nf1Prx1; Psudarthrosis; Tibial dysplasia

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; NEUROFIBROMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BONE DYSPLASIA; CALLUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORTICAL BONE; DETERIORATION; FRACTURE HEALING; FRACTURE NONUNION; GENE INACTIVATION; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; LONG BONE; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; OSSIFICATION; PERIOSTEUM; TUMOR SUPPRESSOR GENE;

ACTINS; ANIMALS; BONE DISEASES, DEVELOPMENTAL; DISEASE MODELS, ANIMAL; FRACTURE HEALING; GENES, NEUROFIBROMATOSIS 1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; TIBIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864942432     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.07.011     Document Type: Article

References (39)

1. Ferguson C., Alpern E., Miclau T., Helms J.A. Does adult fracture repair recapitulate embryonic skeletal formation?. Mech Dev 1999, 87:57-66.
2. Ippolito E., Corsi A., Grill F., Wientroub S., Bianco P. Pathology of bone lesions associated with congenital pseudarthrosis of the leg. J Pediatr Orthop B 2000, 9:3-10.
3. Alwan S., Armstrong L., Joe H., Birch P.H., Szudek J., Friedman J.M. Associations of osseous abnormalities in Neurofibromatosis 1. Am J Med Genet A 2007, 143A:1326-1333.
4. Stevenson D.A., Birch P.H., Friedman J.M., Viskochil D.H., Balestrazzi P., Boni S., et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 1999, 84:413-419.
5. Vitale M.G., Guha A., Skaggs D.L., Vitale M.G., Guha A., Skaggs D.L. Orthopaedic manifestations of neurofibromatosis in children: an update. Clin Orthop Relat Res 2002, 107-118.
6. Serra E., Ars E., Ravella A., Sanchez A., Puig S., Rosenbaum T., et al. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet 2001, 108:416-429.
7. Stevenson D.A., Zhou H., Ashrafi S., Messiaen L.M., Carey J.C., D'Astous J.L., et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006, 79:143-148.
8. Brannan C.I., Perkins A.S., Vogel K.S., Ratner N., Nordlund M.L., Reid S.W., et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994, 8:1019-1029.
9. Schindeler A., Morse A., Harry L., Godfrey C., Mikulec K., McDonald M., et al. Models of tibial fracture healing in normal and Nf1-deficient mice. J Orthop Res 2008, 26:1053-1060.
10. Wang W., Nyman J.S., Moss H.E., Gutierrez G., Mundy G.R., Yang X., et al. Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J Bone Miner Res 2010, 25:1658-1667.
11. Kolanczyk M., Kossler N., Kuhnisch J., Lavitas L., Stricker S., Wilkening U., et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 2007, 16:874-886.
12. Wu X., Chen S., He Y., Rhodes S.D., Mohammad K.S., Li X., et al. The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PLoS One 2011, 6:e24917.
13. El-Hoss J., Sullivan K., Cheng T., Yu N.Y.C., Bobyn J.D., Peacock L., et al. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells. J Bone Miner Res 2012, 27:68-78.
14. Yu X., Chen S., Potter O.L., Murthy S.M., Li J., Pulcini J.M., et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 2005, 36:793-802.
15. Yan J., Chen S., Zhang Y., Li X., Li Y., Wu X., et al. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Hum Mol Genet 2008, 17:936-948.
16. Yang F.C., Chen S., Robling A.G., Yu X., Nebesio T.D., Yan J., et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 2006, 116:2880-2891.
17. Kuorilehto T., Kinnunen P., Nissinen M., Alanne M., Leskela H.V., Lehenkari P., et al. Vasculopathy in two cases of NF1-related congenital pseudarthrosis. Pathol Res Pract 2006, 202:687-690.
18. Lasater E.A., Bessler W.K., Mead L.E., Horn W.E., Clapp D.W., Conway S.J., et al. Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. Hum Mol Genet 2008, 17:2336-2344.
19. Lehrnbecher T., Gassel A.M., Rauh V., Kirchner T., Huppertz H.I. Neurofibromatosis presenting as a severe systemic vasculopathy. Eur J Pediatr 1994, 153:107-109.
20. Kossler N., Stricker S., Rodelsperger C., Robinson P.N., Kim J., Dietrich C., et al. Neurofibromin (Nf1) is required for skeletal muscle development. Hum Mol Genet 2011, 587(20):2697-2709.
21. Kolanczyk M., Kuhnisch J., Kossler N., Osswald M., Stumpp S., Thurisch B., et al. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Med 2008, 6:21.
22. Oni O.O., Stafford H., Gregg P.J. A study of diaphyseal fracture repair using tissue isolation techniques. Injury 1992, 23:467-470.
23. Bonnarens F., Einhorn T.A. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 1984, 2:97-101.
24. Toben D., Schroeder I., El Khassawna T., Mehta M., Hoffmann J.E., Frisch J.T., et al. Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res 2011, 26:113-124.
25. Gerstenfeld L.C., Wronski T.J., Hollinger J.O., Einhorn T.A. Application of histomorphometric methods to the study of bone repair. J Bone Miner Res 2005, 20:1715-1722.
26. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
27. Peters A., Toben D., Lienau J., Schell H., Bail H.J., Matziolis G., et al. Locally applied osteogenic pre-differentiated progenitor cells are more effective than undifferentiated mesenchymal stem cells in the treatment of delayed bone healing. Tissue Eng Part A 2009, 15:2947-2954.
28. Kenner G.H., Hendricks L., Gimenez G., Barb W., Park J.B. Bone embedding technique with inhibited PMMA monomer. Stain Technol 1982, 57:121-126.
29. Cho T.J., Gerstenfeld L.C., Einhorn T.A. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 2002, 17:513-520.
30. Karasek M.A. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease?. Med Hypotheses 2007, 68:650.
31. Sarrazy V., Billet F., Micallef L., Coulomb B., Desmoulière A. Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair Regen September/October 2011, 19(Suppl. s1):s10-s15.
32. Lienau J., Schmidt-Bleek K., Peters A., Haschke F., Duda G.N., Perka C., et al. Differential regulation of blood vessel formation between standard and delayed bone healing. J Orthop Res 2009, 27:1133-1140.
33. Medici D., Shore E.M., Lounev V.Y., Kaplan F.S., Kalluri R., Olsen B.R. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2011, 16:1400.
34. Grcevic D., Pejda S., Matthews B.G., Repic D., Wang L., Li H., et al. In vivo fate mapping identifies mesenchymal progenitor cells. Stem Cells 2012, 30:187-196.
35. Sakamoto A., Yoshida T., Yamamoto H., Oda Y., Tsuneyoshi M., Iwamoto Y. Congenital pseudarthrosis of the tibia: analysis of the histology and the NF1 gene. J Orthop Sci 2007, 12:361-365.
36. Grande M.T., Lopez-Novoa J.M. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009, 5:319-328.
37. Lawton D.M., Andrew J.G., Marsh D.R., Hoyland J.A., Freemont A.J. Mature osteoblasts in human non-union fractures express collagen type III. Mol Pathol 1997, 50:194-197.
38. Mahnken A.H., Staatz G., Hermanns B., Gunther R.W., Weber M. Congenital pseudarthrosis of the tibia in pediatric patients. Am J Roentgenol 2001, 177:1025-1029.
39. Mariaud-Schmidt R.P., Rosales-Quintana S., Bitar E., Fajardo D., Chiapa-Robles G., Gonzalez-Mendoza A., et al. Hamartoma involving the pseudarthrosis site in patients with neurofibromatosis type 1. Pediatr Dev Pathol 2005, 8:190-196.